Skip to content

Wave Life Sciences

US · WVE #3515 by market cap Listed 2015
2.56 -0.16 -5.88%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:33

Price chart

Pre-market 2.66 -2.21%
After-hours 2.60 +1.56%
Overnight 2.69 -1.10%
6.582.562.562026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on WVE?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -56.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 10.5% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D+

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -504.1% Better than 4%
Net margin -478.3% Better than 4%
Return on equity -56.2% Better than 8%
Return on invested capital -53.0% Better than 5%
Momentum F

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -51.6% Better than 5%
6-month return -59.9% Better than 4%
12-month return (ex latest month) -52.5% Better than 2%
Distance below 52-week high 88.2% Better than 1%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.5x Better than 90%
Debt to assets 2.8% Better than 85%
Interest coverage -427.8x Better than 3%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 92.9% Better than 75%
Upside to average target 457.8% Better than 99%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -18.21%
1M -25.15%
3M -51.24%
6M -58.64%
YTD -84.94%
1Y -62.13%
3Y -50.77%
5Y -40.60%

Key statistics

Price & volume

Prev close
2.72
Open
2.65
Day range
2.55 - 2.79
Avg price
2.62
Volume
2.28M
Turnover
5.98M
Amplitude
9.01%
52-week range
2.55 - 21.73

Valuation

P/E
-2.12
P/E (TTM)
-2.39
P/B
1.26
EPS
-1.21
Net profit
-238.65M
Net assets
401.95M

Share structure

Market cap
504.91M
Float cap
268.77M
Shares out
197.23M
Float shares
104.99M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-11-11
52-week range 0% of range
2.55 21.73

88.2% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+5.89M net over the window

Short interest

Shares short
20.65M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Wave Life Sciences (WVE)?

Wave Life Sciences last traded at 2.56. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Wave Life Sciences's market cap?

About 504.91M.

What is the P/E ratio of Wave Life Sciences?

The trailing twelve-month P/E is -2.39. The Valuation tab shows it against the stock's own five-year range.

Does Wave Life Sciences pay a dividend?

Wave Life Sciences does not currently pay a regular dividend.

Is Wave Life Sciences a buy according to analysts?

The consensus of 14 analysts is a Buy rating, with an average 12-month price target of 14.28, which implies 457.8% upside from the current price. This is not investment advice.

What is Wave Life Sciences's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Wave Life Sciences a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:33:51 · For reference only, not investment advice and not tailored to your situation.

Wave Life Sciences discussion 0 comments

Add a comment